Why travel shares are getting slammed…and it is not for the reasons you may think
Just when ASX travel shares were out of the COVID-19 doldrums (in that some surpassed their pre-COVID highs), 2025 looks…
Capital Gains Tax on Stocks: Here’s what you need to know
Investors may be liable to pay Capital Gains Tax on Stocks, but may not know the nuances of how it…
BHP or RIO Tinto? Which of these 2 resources giants is the better investment and which one has upside?
BHP or Rio Tinto? Choosing between these two major miners is no easy feat. In this article, we take a…
EBR Systems (ASX:EBR): Another heart-focused medtech that has gained FDA approval
Mere days after Artrya (ASX:AYA) obtained FDA approval for its heart-health technology, EBR Systems (ASX:EBR) has achieved that same feat.…
ASX 200 Winners: Here are 6 that have slipped under the radar
A quick glance of the list of ASX 200 Winners in 2025 would throw up many obvious candidates. The majority…
Will Trump Make Uranium Great Again? And either way, what’s next for uranium stocks
Uranium investors hoping the Trump administration would ‘Make Uranium Great Again’ have been disappointed so far, but should investors give…
Nvidia’s Stock Is Sliding Again: Is It Time to Buy the Dip—or Stay on the Sidelines?
Nvidia, a giant in the semiconductor industry and a leader in graphics processing units (GPUS), has been driving some of…
Trump’s Tariff Pause Gave Nvidia a Lift—But Will It Last?
In early April 2024, Nvidia found itself benefiting from an unexpected source of optimism: US politics. The Biden administration announced…
St George Mining (ASX:SGQ) finds its ‘company maker’ in Brazil
When St George Mining (ASX:SGQ) announced last August that it was acquiring its Araxa project in Brazil, investors could be…
BHP shares have the ASX’s highest valuation at $180BN – but are they worth it?
BHP shares are the ASX’s second most valuable, with the company capped at over A$180bn. Only CBA (ASX:CBA) usurps it,…
Neuren Pharmaceuticals (ASX:NEU): Another exciting chapter is yet to come with NNZ-2591
Neuren Pharmaceuticals (ASX:NEU) is an ASX biotech company that has had a stellar past few years, but it is now…
What the Tariff Pause Means for Apple: Can the Stock Continue Its Recovery?
After shedding nearly 30% of their value between December 24 last year and April 8 this year, shares in Apple…
CSL (ASX:CSL): Its promised double-digit earnings growth for the rest of the 2020s, but will Trump’s tariffs shatter the dream?
CSL has been hit more than most other stocks due to Trump tariffs. While many companies being sold off merely…
When do you know it’s time to ‘buy the dip’? You could be catching a falling knife
‘Buy the dip’ – have you ever heard that term? It implies that when a company’s share price ‘dips’ or decreases,…